Human medicines European public assessment report (EPAR): Usrenty, ustekinumab, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

17 February 2026

Minutes of the CHMP meeting 21-24 July 2025

16 February 2026

Minutes of the CHMP meeting 19-22 May 2025

16 February 2026

Clinical Pharmacology Operational Expert Group

16 February 2026

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised

16 February 2026

PSUSA/00010606/202506

16 February 2026

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/2016, Revision: 18, Status: Authorised

16 February 2026

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised

16 February 2026

Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026

16 February 2026

Human medicines European public assessment report (EPAR): Orphacol, cholic acid, Date of authorisation: 12/09/2013, Revision: 16, Status: Authorised

16 February 2026